During Q4 2018 the big money sentiment increased to 1.21. That’s change of 0.07, from 2018Q3’s 1.14. 32 investors sold all, 59 reduced holdings as Integra LifeSciences Holdings Corporation ratio improved. 74 increased positions while 36 funds took positions. Funds hold 70.91 million shares thus 1.24% less from 2018Q3’s 71.80 million shares.
Whittier Tru Com has 3,344 shs for 0.01% of their capital. Moreover, Mutual Of America Capital Management Limited Liability Corporation has 0.05% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Rhumbline Advisers reported 0.02% stake. Great West Life Assurance Can owns 43,955 shs for 0.01% of their capital. Asset One Limited accumulated 20,903 shs. Oakbrook Invests Ltd reported 8,400 shs stake. Falcon Point Capital Limited Liability Company accumulated 84,255 shs. 723,578 were reported by Dimensional Fund Advisors Lp. Moreover, California Public Employees Retirement has 0.01% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Prelude Cap Ltd Liability Corp invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 5,071 shs. Clearbridge Investments Limited Liability Corporation invested in 2.02M shs. Credit Suisse Ag has invested 0% of its capital in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Teachers Retirement Sys Of The State Of Kentucky reported 73,106 shs stake. Renaissance Techs Limited Liability Company holds 0.01% or 148,360 shs.

Investors expect Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s quarterly earnings on April, 24., as reported by Faxor. Analysts have expectation on stock’s earnings per share of $0.61. That’s up 5.17 % from last year’s $0.58 earnings per share. In case of $0.61 earnings per share IART’s profit could be $51.99 million. Wall Street now predicts -6.15 % negative EPS growth despite Integra LifeSciences Holdings Corporation last quarter’s EPS of $0.65. The stock increased 1.02% or $0.55 during the last trading session, reaching $54.43.Integra LifeSciences Holdings Corporation has volume of 373,941 shares. Since April 7, 2018 IART has risen 8.33% and is uptrending. The stock outperformed the S&P 500 by 3.96%.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

In total 11 analysts cover Integra Lifesciences (NASDAQ:IART). “Buy” rating has 5, “Sell” are 0, while 6 are “Hold”. 45% are bullish. 18 are the (NASDAQ:IART)’s analyst reports since October 11, 2018 according to StockzIntelligence Inc. On Thursday, October 11 the firm earned “Equal-Weight” rating by Morgan Stanley. On Thursday, February 21 BTIG Research maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) with “Buy” rating. On Friday, November 2 the firm earned “Market Outperform” rating by JMP Securities. The company rating was maintained by Piper Jaffray on Monday, March 11. On Friday, February 22 the firm has “Hold” rating by Citigroup given. On Tuesday, February 26 JMP Securities maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating. JMP Securities has “Buy” rating and $62 target. On Friday, November 2 the rating was maintained by Citigroup with “Neutral”. On Thursday, November 1 Wells Fargo maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating. Wells Fargo has “Market Perform” rating and $55 target. On Friday, February 22 RBC Capital Markets maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating. RBC Capital Markets has “Hold” rating and $57 target. On Thursday, November 1 the stock has “Neutral” rating by Cantor Fitzgerald.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The company has $4.64 billion market cap. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.The P/E ratio is 75.6. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

For more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news posted recently go to: Nasdaq.com, Globenewswire.com, Nasdaq.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Here’s Why You Should Buy Integra LifeSciences (IART) Stock – Nasdaq” posted on June 22, 2018, “Integra LifeSciences Launches the Integra® Panta® 2 TTC Arthrodesis Nail System – GlobeNewswire” on February 13, 2019, “Health Care Sector Update for 02/21/2019: IART,NUVA,JNJ – Nasdaq” with a publish date: February 21, 2019, “Integra LifeSciences Selected for Healogics iSupply Program – GlobeNewswire” and the last “Integra LifeSciences Holdings (IART) CEO Peter Arduini on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: October 31, 2018.